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Exploiting DNA repair defects for novel cancer 
therapies
ABSTRACT Most human tumors accumulate a multitude of genetic changes due to defects 
in the DNA damage response. Recently, small-molecule inhibitors have been developed that 
target cells with specific DNA repair defects, providing hope for precision treatment of such 
tumors. Here we discuss the rationale behind these therapies and how an important bottle-
neck—patient selection—can be approached.
DNA DAMAGE RESPONSE AND TUMORIGENESIS
The DNA damage response (DDR) safeguards genetic information 
stored in DNA. This cellular defense mechanism against DNA injury 
is of utmost importance for the avoidance of cancer and aging 
symptoms (Hoeijmakers, 2001; Vermeij et al., 2016). The DDR con-
sists of a complex network of cell cycle–progression checkpoint 
pathways, as well as multiple DNA repair pathways. In the context of 
cancer, defects in the DDR are seen as a hallmark of tumor cells 
(Hanahan and Weinberg, 2011). A defective DDR not only promotes 
the initiation of cancer, but it also allows the tumor cells to quickly 
acquire (advantageous) mutations during their evolution. Here we 
will concentrate on defects in DNA repair mechanisms and DNA 
metabolism and how these defects can be exploited for precision 
treatment of selected tumors.
Several cancer predisposition syndromes have highlighted the 
importance of DNA repair for cancer prevention (Knoch et al., 2012). 
A classic example is xeroderma pigmentosum, in which defective 
nucleotide excision repair causes ultraviolet (UV)-induced skin can-
cer. This recessive genetic disease allows accumulation of a large 
numbers of point mutation in UV-exposed skin cells of patients, 
leading to multiple tumors at a very young age.
The etiology of hereditary mammary and ovarian cancer was 
unraveled more recently (Prakash et al., 2015). Defects in the 
BRCA1 or BRCA2 gene result in a very high chance of developing 
breast or ovarian cancer. Both BRCA proteins are required for effi-
cient DNA double-strand break (DSB) repair by homologous re-
combination (HR). In this case, the inheritance pattern is dominant. 
The disease-causing mutation is present in heterozygous form in 
all cells, whereas the tumor cells lose the remaining functional 
allele.
DNA DSB REPAIR
DSBs are among the most toxic types of DNA damage. If left unre-
paired, they can result in loss of chromosome fragments during mi-
tosis and possible loss of heterozygosity for essential tumor sup-
pressor genes. Incorrect repair of DNA ends, on the other hand, can 
result in chromosomal translocations, which are the driving muta-
genic events in many tumors (Janssen and Medema, 2013; Iliakis 
et al., 2015). However, efficient DSB repair pathways have evolved 
(Chapman et al., 2012; Brandsma and Gent, 2012; Jeggo and 
Löbrich, 2015). The two major pathways are mechanistically distinct. 
The simplest and most widely used pathway is nonhomologous end 
joining (NHEJ), which couples both DNA ends by direct ligation. 
Classic NHEJ depends on the DNA-dependent protein kinase and 
ligase IV complexes, but alternative, more error-prone mechanisms 
also exist. HR, on the other hand, is a quite intricate mechanism that 
uses the homologous sequence on the sister chromatid for precise 
repair of the DSB. This DNA repair pathway is mainly active in the S 
and G2 phases of the cell cycle, as it needs a sister chromatid as 
repair template.
In addition to direct DSBs, DNA breaks can also appear indirectly 
during replication of a damaged DNA template or as intermediates 
in repair of interstrand cross-links, a covalent linkage between bases 
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bridge this diagnostic gap. Conditions for culturing thin tumor slices 
for several days without loss of viability or proliferative capacity have 
been developed, which allow direct drug sensitivity testing on fresh 
tumor material (Naipal et al., 2014, 2016). The predictive power of 
this approach needs to be established, but most technical hurdles 
for direct testing on tumor biopsies have been removed. In combi-
nation with new predictive biomarkers, these functional tests pave 
the way for selection of the optimal treatment regimen for each in-
dividual patient.
In addition to genetic or epigenetic changes in the tumor, HR 
deficiency can also be induced locally. Mild hyperthermia (41–42°C) 
induces BRCA2 protein degradation, resulting in severely reduced 
HR capacity in cells and tissues (Krawczyk et al., 2011). Because heat 
can be applied locally in the patient (Issels et al., 2016; van den 
Tempel et al., 2016), PARP inhibitor sensitivity can be increased in all 
tumors that can be heated in a controlled way.
In general, PARP inhibition is seen as a promising new targeted 
anticancer treatment. This is clear from the extensive number of on-
going clinical trials, ranging from phase I to phase III, involving a 
number of PARP inhibitors, such as niraparib (MK4827), olaparib 
(AZD2281), rucaparib (AG014699), talazoparib (BMN 673), and veli-
parib (ABT-888; Donawho et al. 2007; Evers et al. 2008; Plummer 
et al. 2008; Jones et al. 2009; Shen et al. 2013).. The trials test PARP 
inhibitors either as monotherapy or in combination with chemother-
apy or radiotherapy and are not limited to BRCA mutant patients or 
to breast and ovarian cancer sites (O’Connor, 2015).
OTHER TREATMENTS TARGETING THE DNA DAMAGE 
RESPONSE
Although originally considered a collection of linear pathways, the 
DDR is now seen as a complex interconnected and dynamic net-
work of numerous pathways capable of shuttling repair intermedi-
ates between different pathways (Wyman and Kanaar, 2006; Al-Ejeh 
et al., 2010). This ability provides the rationale for why PARP inhibi-
tors of single-strand break repair are synthetic lethal in HR-defective 
cells. Indeed, PARP inhibition defined the concept of synthetic le-
thality in the context of the DDR (Lord and Ashworth, 2008). Given 
that the DDR consists of multiple pathways, other examples of syn-
thetic lethality involving tumor-specific DDR defects are to be ex-
pected in the near future. Their rational design would require mech-
anistic insight into the interplay and interdependences among DDR 
pathways.
More recently, MutT homologue 1 (MTH1) inhibition has been 
explored as a precision therapy for cancer (Gad et al., 2014; Huber 
et al., 2014). This approach does not directly focus on DNA but on 
deoxynucleoside triphosphates (dNTPs), the building block of DNA. 
Just as a defective DDR is one of the hallmarks of cancer, so is 
deregulation of cellular metabolism, including redox regulation. 
Indeed, the level of reactive oxygen species (ROS) is generally 
increased in cancer cells, not only resulting in more direct DNA le-
sions but also contributing indirectly to DNA damage by incorpora-
tion of damaged dNTPs. Oxidized dNTPs form a substantial threat 
to DNA integrity, as the dNTP pool is much more susceptible to oxi-
dation compared with bases already incorporated in DNA (Topal 
and Baker, 1982). The enzyme MTH1 removes the high-energy 
phosphate bond from the damaged dNTPs such that they can no 
longer be incorporated in DNA by a DNA polymerase (Sakumi 
et al., 1993). Given the difference in ROS levels between normal and 
cancer cells, the latter may depend much more strongly on MTH1 to 
prevent deleterious DNA damage. Therefore inhibitors of MTH1 are 
expected to preferentially affect cancer cells, a prediction that is 
supported in some experimental settings (Gad et al., 2014) but does 
in opposite DNA strands (Zeman and Cimprich, 2014; Zhang and 
Walter, 2014). In these cases, NHEJ cannot properly repair the le-
sion. Replication-associated DSBs arise, for example, when the rep-
lication fork encounters a single-strand break, resulting in a single 
DNA end, which cannot be repaired by NHEJ because of the lack of 
a second DNA end. Therefore this DNA end needs to be reinserted 
by HR into the DNA double helix that is being replicated in order to 
restart the replication fork.
HR is initiated by resection of the DNA end, which is carried out 
by nucleases such that 3′-ended single-strand DNA tails are formed 
(Symington, 2014; Cejka, 2015). Formation of these protrusions also 
requires active BRCA1 protein, explaining the HR defect caused by 
mutation of this gene (Sartori et al., 2007; Jasin and Rothstein, 
2013). RPA protein accumulates on the single-stranded DNA, which 
is subsequently replaced by the RAD51 protein. The accumulation 
of RAD51 protein at DSBs depends on BRCA2 and can be visualized 
as RAD51 protein foci by immunofluorescence microscopy (Yuan 
et al., 1999). The RAD51–single-strand DNA complex recognizes 
homology on the intact sister chromatid, which it uses to copy lost 
DNA fragments or restart a replication fork.
EXPLOITING BRCA GENE DEFECTS IN BREAST 
AND OVARIAN CANCER
The selective inactivation of HR capacity in hereditary breast and 
ovarian cancer not only provides an explanation for the chromo-
somal instability of these tumors, but it may also be the Achilles heel 
of the tumor cells (O’Connor, 2015). The HR defect makes these 
cells very sensitive to treatments that increase the number of single-
strand breaks encountered by replication forks. This can be done by 
inhibition of one of the enzymes involved in single-strand break re-
pair, the poly-[ADP-ribose]-polymerase 1 (PARP1) protein. Several 
small-molecule inhibitors kill BRCA1 and BRCA2 defective cells very 
efficiently (Bryant et al., 2005; Farmer et al., 2005). In vitro, BRCA-
deficient cells were ∼1000-fold more sensitive to PARP inhibitors 
than their proficient counterparts. This so-called synthetic lethality 
approach was quickly taken to animal experiments and early clinical 
studies. The effects for BRCA-mutated ovarian tumors were so clear 
that the phase II clinical study resulted in a clear progression-free 
survival benefit with relatively mild side effects (Fong et al., 2009). 
This led to approval of the PARP inhibitor olaparib for the European 
and American markets. Results for breast cancer were less clear and 
await completion of phase III trials.
In addition to germline BRCA gene mutations in ovarian cancers 
(14% of the cases), somatic mutations in these genes have been 
found in 6% of ovarian tumors (De Picciotto et al., 2016). Further-
more, gene inactivation can also be epigenetic; BRCA1 promoter 
methylation has been found in another 11% of ovarian cancers. It is 
not clear whether these methylation events are present in the entire 
tumor and whether they are sufficiently stable for effective thera-
peutic use. However, it is clear that a sizeable fraction of these tu-
mors will be eligible for PARP inhibitor treatment.
EXTENDING THE USE OF PARP INHIBITORS
From the rationale behind the effectiveness of PARP inhibitors, it 
follows that not only should BRCA-deficient tumors be PARP inhibi-
tor sensitive, but so should also tumors with a defect in HR, irrespec-
tive of BRCA inactivation. A number of HR genes are known, such as 
RAD51 and the gene encoding the BRCA2-interacting protein, 
PALB2 (Liu et al., 2014). However, rather than analyzing individual 
genes with genomics techniques, one would rather functionally test 
for HR deficiency and/or PARP inhibitor sensitivity. Recent develop-
ments in ex vivo functional assays on primary tumor material could 
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require further careful experimentation for validation (Kettle et al., 
2016).
Besides the enzymes directly governing cell cycle check points 
and DNA repair, a number of sensor and transducer kinases form a 
pivotal part of the DNA damage response (Velic et al., 2015). Several 
small-molecule inhibitors of these kinases are being tested in early-
stage clinical trials for a wide variety of cancers (O’Connor, 2015). 
The major challenge will be to find the optimal inhibitors and match 
them for efficacy with specific DDR defects in tumors.
THE DNA DAMAGE RESPONSE AS PROMISING SOURCE 
FOR PATIENT SELECTION METHODS AND PRECISION 
CANCER THERAPIES
Concomitant with the development of precision cancer therapies 
based on the DDR, including those described earlier, diagnostic 
tools will be indispensable for proper therapy selection of individual 
patients. Because simple robust and reliable biomarkers are often 
difficult to find, direct functional testing on fresh biopsy material or 
cancer organoid cultures may be the way to go for many novel ther-
apies. The added advantage of a functional test over a DNA diag-
nostic test is that it reports on the combined activity of many reac-
tion steps in a pathway, which is expected to enable detection of 
many more patients eligible for specific precision therapy. To realize 
this form of testing, ex vivo culture methods should be optimized 
(Davies et al., 2015), miniaturized, and automated in order to allow 
multiple functional assays on the limited amount of material avail-
able in a cancer-on-chip approach (van de Stolpe A and den 
Toonder, 2013; Hickman et al., 2014; Benam et al., 2015). It is clear 
that precision medicine will require precision diagnosis, which is 
best done by testing for biological function. Successful implementa-
tion of these diagnostic tools will depend not only on the predictive 
value of the test, but also on the practicability, cost, and speed of 
the assay.
REFERENCES
Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, Khanna KK (2010). 
Harnessing the complexity of DNA-damage response pathways to 
improve cancer treatment outcomes. Oncogene 29, 6085–6098.
Benam KH, Dauth S, Hassell B, Herland A, Jain A, Jang KJ, Karalis K, Kim 
HJ, MacQueen L, Mahmoodian R, et al. (2015). Engineered in vitro 
disease models. Annu Rev Pathol 10, 195–262.
Brandsma I, Gent DC (2012). Pathway choice in DNA double strand break 
repair: observations of a balancing act. Genome Integr 3, 9.
Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, 
Meuth M, Curtin NJ, Helleday T (2005). Specific killing of BRCA2-defi-
cient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 
434, 913–917.
Cejka P (2015). DNA end resection: nucleases team up with the right 
partners to initiate homologous recombination. J Biol Chem 290, 
22931–22938.
Chapman JR, Taylor MR, Boulton SJ (2012). Playing the end game: DNA 
double-strand break repair pathway choice. Mol Cell 47, 497–510.
Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj 
A, Metsalu T, Oswald E, Erkens-Schulze S, et al. (2015). Capturing com-
plex tumour biology in vitro: histological and molecular characterisation 
of precision cut slices. Sci Rep 5, 17187.
De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI (2016). 
Ovarian cancer: status of homologous recombination pathway as a 
predictor of drug response. Crit Rev Oncol Hematol 101, 50–59.
Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-
Diaz VD, Cox BF, DeWeese TL, Dillehay LE, et al. (2007). ABT-888, an 
orally active poly(ADP-ribose) polymerase inhibitor that potentiates 
DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13, 
2728–2737.
Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, 
Holstege H, Liu X, van Drunen E, Beverloo HB, et al. (2008). Selective 
inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 
and cisplatin. Clin Cancer Res 14, 3916–3625.
Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, 
Santarosa M, Dillon KJ, Hickson I, Knights C, et al. (2005). Targeting 
the DNA repair defect in BRCA mutant cells as a therapeutic strategy. 
Nature 434, 917–921.
Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, 
Swaisland H, Lau A, O’Connor MJ, et al. (2009). Inhibition of poly(ADP-
ribose) polymerase in tumors from BRCA mutation carriers. N Engl J 
Med 361, 123–134.
Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson 
LM, Schultz N, Lundbäck T, Einarsdottir BO, et al. (2014). MTH1 inhibi-
tion eradicates cancer by preventing sanitation of the dNTP pool. Nature 
508, 215–221.
Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. 
Cell 144, 646–674.
Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der 
Kuip HIMI PREDECT Consortium (2014). Three-dimensional models 
of cancer for pharmacology and cancer cell biology: capturing tumor 
complexity in vitro/ex vivo. Biotechnol J 9, 1115–1128.
Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing 
cancer. Nature 411, 366–374.
Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, 
Göktürk C, Sanjiv K, Strömberg K, et al. (2014). Stereospecific target-
ing of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 508, 
222–227.
Iliakis G, Murmann T, Soni A (2015). Alternative end-joining repair pathways 
are the ultimate backup for abrogated classical non-homologous end-
joining and homologous recombination repair: Implications for the for-
mation of chromosome translocations. Mutat Res Genet Toxicol Environ 
Mutagen 793, 166–175.
Issels R, Kampmann E, Kanaar R, Lindner LH (2016). Hallmarks of hy-
perthermia in driving the future of clinical hyperthermia as targeted 
therapy: translation into clinical application. Int J Hyperthermia 32, 
89–95.
Janssen A, Medema RH (2013). Genetic instability: tipping the balance. 
Oncogene 32, 4459–4470.
Jasin M, Rothstein R (2013). Repair of strand breaks by homologous recom-
bination. Cold Spring Harb Perspect Biol 5, a012740.
Jeggo PA, Löbrich M (2015). How cancer cells hijack DNA double-strand 
break repair pathways to gain genomic instability. Biochem J 471, 
1–11.
Jones P, Altamura S, Boueres J, Ferrigno F, Fonsi M, Giomini C, Lamartina 
S, Monteagudo E, Ontoria JM, Orsale MV, et al. (2009). Discovery of 
2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): 
a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in 
BRCA-1 and -2 mutant tumors. J Med Chem 52, 7170–7185.
Kettle JG, Alwan H, Bista M, Breed J, Davies NL, Eckersley K, Fillery S, 
Foote KM, Goodwin L, Jones DR, et al. (2016). Potent and selective 
inhibitors of MTH1 probe its role in cancer cell survival. J Med Chem 59, 
2346–2361.
Knoch J, Kamenisch Y, Kubisch C, Berneburg M (2012). Rare hereditary 
diseases with defects in DNA-repair. Eur J Dermatol 22, 443–455.
Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H, Zelensky 
A, van Bree C, Stalpers LJ, Buist MR, et al. (2011). Mild hyperthermia 
inhibits homologous recombination, induces BRCA2 degradation, and 
sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc 
Natl Acad Sci USA 108, 9851–9856.
Liu C, Srihari S, Cao KA, Chenevix-Trench G, Simpson PT, Ragan MA, 
Khanna KK (2014). A fine-scale dissection of the DNA double-strand 
break repair machinery and its implications for breast cancer therapy. 
Nucleic Acids Res 42, 6106–6127.
Lord CJ, Ashworth A (2008). Targeted therapy for cancer using PARP inhibi-
tors. Curr Opin Pharmacol 8, 363–369.
Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, 
Meijers M, Sieuwerts AM, Martens JW, O’Connor MJ, Vrieling H, et al. 
(2014). Functional ex vivo assay to select homologous recombination-
deficient breast tumors for PARP inhibitor treatment. Clin Cancer Res 20, 
4816–4826.
Naipal KA, Verkaik NS, Sánchez H, van Deurzen CH, den Bakker MA, 
Hoeijmakers JH, Kanaar R, Vreeswijk MP, Jager A, van Gent DC (2016). 
Tumor slice culture system to assess drug response of primary breast 
cancer. BMC Cancer 16, 78.
O’Connor MJ (2015). Targeting the DNA damage response in cancer. Mol 
Cell 60, 547–560.
Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, Curtin 
N, Boddy A, McHugh P, Newell D, et al. (2008). Phase I study of the 
poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with 
2148 | D. C. van Gent and R. Kanaar Molecular Biology of the Cell
temozolomide in patients with advanced solid tumors. Clin Cancer Res 
14, 7917–7923.
Prakash R, Zhang Y, Feng W, Jasin M (2015). Homologous recombination 
and human health: the roles of BRCA1, BRCA2, and associated proteins. 
Cold Spring Harb Perspect Biol 7, a016600.
Sakumi K, Furuichi M, Tsuzuki T, Kakuma T, Kawabata S, Maki H, Sekiguchi 
M (1993). Cloning and expression of cDNA for a human enzyme that 
hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. J Biol 
Chem 268, 23524–23530.
Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, Bartek J, Baer R, Lukas J, 
Jackson SP (2007). Human CtIP promotes DNA end resection. Nature 
450, 509–514.
Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord 
CJ, Post LE, Ashworth A (2013). BMN 673, a novel and highly potent 
PARP1/2 inhibitor for the treatment of human cancers with DNA repair 
deficiency. Clin Cancer Res 19, 5003–5015.
Symington LS (2014). End resection at double-strand breaks: mechanism 
and regulation. Cold Spring Harb Perspect Biol 6, a016436.
Topal MD, Baker MS (1982). DNA precursor pool: a significant target for 
N-methyl-N-nitrosourea in C3H/10T1/2 clone 8 cells. Proc Natl Acad Sci 
USA 79, 2211–2215.
van den Tempel N, Horsman MR, Kanaar R (2016). Improving efficacy of 
hyperthermia in oncology by exploiting biological mechanisms. Int J 
Hyperthermia Apr 18, 1–9.
van de Stolpe A, den Toonder J (2013). Workshop meeting report Organs-
on-Chips: human disease models. Lab Chip 13, 3449–3470.
Velic D, Couturier AM, Ferreira MT, Rodrigue A, Poirier GG, Fleury F, 
Masson JY (2015). DNA Damage signalling and repair inhibitors: 
the long-sought-after achilles’ heel of cancer. Biomolecules 5, 
3204–3259.
Vermeij WP, Hoeijmakers JH, Pothof J (2016). Genome integrity in aging: 
human syndromes, mouse models, and therapeutic options. Annu Rev 
Pharmacol Toxicol 56, 427–445.
Wyman C, Kanaar R (2006). DNA double-strand break repair: all's well that 
ends well. Annu Rev Genet 40, 363–383.
Yuan SS, Lee SY, Chen G, Song M, Tomlinson GE, Lee EY (1999). BRCA2 is 
required for ionizing radiation-induced assembly of Rad51 complex in 
vivo. Cancer Res 59, 3547–3551.
Zeman MK, Cimprich KA (2014). Causes and consequences of replication 
stress. Nat Cell Biol 16, 2–9.
Zhang J, Walter JC (2014). Mechanism and regulation of incisions during 
DNA interstrand cross-link repair. DNA Repair 19, 135–142.
